The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1609
Two New Doses of Dulaglutide (Trulicity) for Diabetes
Download PDF:    US English
 Select a term to see related articles  dulaglutide   Metformin   Trulicity   type 2 diabetes 

The FDA has approved two additional doses (3 mg and 4.5 mg) of the glucagon-like peptide-1 (GLP-1) receptor agonist dulaglutide (Trulicity – Lilly) for treatment of type 2 diabetes in adults. Dulaglutide has been available in 0.75- and 1.5-mg doses for years.1

CLINICAL STUDIES — Approval of the two new doses was based on the results of a double-blind trial (AWARD-11; summarized in the package insert) that randomized 1842 patients with type 2 diabetes inadequately controlled on metformin monotherapy to receive dulaglutide 1.5, 3, or 4.5 mg SC once weekly. Reductions from baseline in A1C and weight at 36 weeks were statistically significantly greater with dulaglutide 4.5 mg (but not with 3 mg) than with the 1.5-mg dose.

ADVERSE EFFECTS — The most common adverse effects of dulaglutide in AWARD-11 were nausea, diarrhea, and vomiting; the incidences of these adverse effects were similar with all three doses.

DOSAGE AND COST — Dulaglutide is available in 0.75-, 1.5-, 3-, and 4.5-mg single-dose pens. The recommended starting dosage in the US is 0.75 mg SC once weekly. The weekly dose can be increased by 1.5 mg every 4 weeks as needed to a maximum of 4.5 mg. The 3- and 4.5-mg single-dose pens cost the same as the 0.75- and 1.5-mg pens. The cost of 4 weeks’ treatment with dulaglutide is about $800.2

REFERENCES

© The Medical Letter, Inc. All Rights Reserved.
This article has been freely provided.